Friday 16 October 2026
Export GLSI’s income statement to Excel — free account
Greenwich LifeSciences, Inc.
GLSI Healthcare Biotechnology
In the quarter to June 2026, EPS grew 10.0% and free cash flow grew 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.55
0.77
−5.03%
Follow GLSI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
1.54 | 2.01 | 1.06 | 2.35 |
+8 more quarters Free account |
Net Debt/EBITDA |
2.21 | 1.83 | 0.71 | 0.91 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.49 | 0.83 | 0.36 | 0.64 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.13) | (0.32) | (0.23) | (0.20) | |
Cash per Share |
0.61 | 0.72 | 0.46 | 0.28 | |
Shareholders Equity per Share |
0.21 | 0.36 | 0.03 | 0.16 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.21 | 0.36 | 0.03 | 0.16 | |
Free Cash Flow |
(1.94) | (4.70) | (3.17) | (2.67) | |
Working Capital |
3.12 | 5.27 | 0.35 | 2.19 | |
Net Current Asset Value |
3.12 | 5.27 | 0.35 | 2.19 | |
| Other line items | |||||
Quick Ratio |
1.54 | 2.01 | 1.06 | 2.35 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.13) | (0.32) | (0.23) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
3.16 | 2.78 | 3.84 | 0.94 | |
Average Assets |
6.00 | 6.63 | 5.14 | 4.82 | |
Average Common Equity |
2.28 | 3.29 | 0.63 | 3.58 |
Columns are period end dates